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The Value of Nothing
The Consequence of a
Negative Troponin Test*
W. Frank Peacock, MD
Cleveland, Ohio
As an emergency department (ED) doctor, I liked this
study. Why? Because emergency doctors send patients
home. To send a patient home means that he or she lives or
dies based on the negative predictive value of the test I just
ordered. It is why the study by Body et al. (1), in this issue
of the Journal, which presents data on the value of a low
troponin, is important. Most studies report specificity.
Highly specific troponin assays accurately predict the diag-
nosis of acute myocardial infarction and the need for cardiac
catheterization and are clinically helpful. However, the
consequence of high specificity is poor sensitivity. Tests
with poor sensitivity are of little use to make a discharge
decision, and honestly are dangerous if used as the sole basis
for a discharge decision. The clinical consequence of a
poorly sensitive test means that if I discharge Mr. Jones,
who is sitting in front of me, on the basis of a negative test,
he is sent home and perhaps dies of a myocardial infarc-
tion—not quite the outcome either one of us was hoping
for.
See page 1332
Thus, the focus of this study, in that it attempts to define
the value of a negative high-sensitivity troponin, represents
an important consequence with significant clinical value. In
fact, if you consider the annual 6 million Americans who
seek treatment at the ED for chest pain and eventually are
ruled out for myocardial infarction (2), an initially negative
troponin (occurring in approximately 85%) will impact more
patients than the positive result (3).
Highly specific but insensitive tests, such as the currently
available United States troponin assays, scare me to death.
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negative result means absolutely nothing. Specificity is great
in that it indicates who needs an intervention. But this is an
interventional cardiologist’s endpoint and does not work for
those who must send patients home from the ED. Ponder
this: if you are a cardiologist, most folks on your service will
have at least some probability of having a cardiac reason for
being there. Not so in the ED. Well described is the fact
that few patients with chest pain seeking treatment in the
ED will have positive troponin results (3). This is because
the overwhelming majority do not even have coronary artery
disease. Most have something more mundane, such as
indigestion or a muscle cramp. So what good is a test that
is negative in more than 85% and has no negative predictive
value for excluding myocardial necrosis? The answer is “not
much.” This is the reason why negative troponin results
have not been helpful for ED clinical decision making. It is
also why every single professional society guideline says
“repeat if initially negative” (although there is no agreement
as to the timing of when it should be repeated).
Enter the era of high-sensitivity troponin, with more
positive test results than we have ever seen before. Although
some bemoan that fact that in the setting of most patients
having a detectable troponin, we can no longer have the
knee-jerk response that it equates to a trip to the catheter-
ization laboratory, the new reality is that every single
troponin elevation above the 99th percentile is associated
with increased mortality. It is only a matter of timing. There
is no such thing as a “good” troponin elevation. So although
it may not be a myocardial infarction in terms of the
universal definition (4), from the ED point of view, in a
patient with elevated troponin, an immediate discharge is
neither the best nor safest strategy.
In this study by Body et al. (1), the consequences of low
high-sensitivity troponin results are presented. The real value is
the finding that if the initial troponin is 3 pg/ml, further
troponin testing adds little to outcome prediction. Some will
criticize the fact that only 17.5% of the chest pain cohort would
be ruled out on the basis of this single test, saying this number
is too small for clinical relevance. However, consider that the
numbers of patients currently undergoing a rule-out strategy in
the United States are so large that if applied here, there could
be significant economic benefit to both patients and providers.
It is a new era where a rule out means exactly that: acute
myocardial infarction has been ruled out. Hence, we are
witnesses to the beginning of the death of the serial biomarker
strategy. But do not become too excited; important issues
remain, including: 1) unstable angina still lurks; and 2) patients
do not always get their stories straight.
Of import is that although troponin provides evidence of
dead myocardium, it has yet to be proven that its absence
excludes unstable angina. Whether ischemic, but not dead,
myocardium can be detected by the newest high-sensitivity
troponin assays remains a point of controversy. Currently, the
safest strategy is probably that recommended by the Society of
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excluded, an evaluation of myocardial perfusion provides the
safest disposition information for the patient. Whether this
means stress testing, echocardiography, or computed tomo-
graphic coronary angiography is unclear, and whether that
should be carried out immediately or simply in the next several
days is undefined, but it seems reasonable that the exclusion of
necrosis alone does not provide adequate short-term safety.
The second problem is: can you trust your patient? With
the redefinition of myocardial infarction, we now use
chemistry to define it. Obviously, this is an improved
concept over the old definition. But have we opened
Pandora’s box? This study demonstrates that we can exclude
the presence of newly necrotic myocardium in patients with
chest pain by the performance of an improved assay. But is
that the end game? Are we done if part of the heart did not
die? Thus, this is the challenge of the clinical evaluation in
2011. In the past, in a patient seeking treatment in the ED,
chest pain begat an evaluation, an evaluation begat a
diagnosis, and those who did not have chest pain were not
included. But now that we can detect picogram levels of
troponin, is this good enough? Historically, chest pain
defined the pretest odds for the need to test for troponin
level, and in the absence of chest pain, troponin testing was
optional. What has occurred now, since we moved the
definition, is that we also have moved the entry criteria. In
a compelling study published by Canto et al. (5), nearly one
third of more than 400,000 myocardial infarction patients
did not have chest pain. Instead, they had nonspecific
symptoms such as syncope, shortness of breath, or weak-
ness. What would be the clinical impact of applying the
strategy of Body et al. to an all-comers population? How
their high-sensitivity test fits in the expanded catchment of
a nonchest pain population is unclear, a point that will need
to be answered by future studies.
Other critical limitations exist before the results of this
study can be applied to U.S. clinical practice. The most
important is that the assay that Body et al. (1) used is not
available in the United States, and the assays that have been
cleared by the Food and Drug Administration are not proven
to meet this standard. Thus, we must wait for the regulators to
catch up to that which we think we already know.
Although it is reassuring that in the Body et al. (1)
analysis, only 1 patient had an adverse event in the 30 days
after ED discharge, there are study design considerations in
a European strategy that must be considered if it is to be
applied to U.S. practice style. European studies consistently
have markedly higher rule-in rates, and their litigation
climate is not nearly as toxic compared with the United
States. The implication of this is that the higher the rule-in
rate, the easier is it for an assay to seem accurate in excluding
disease (because there are fewer opportunities for misses),
but as the rule-in rate declines, with greater numbers of
patients having negative test results, the opportunity for
false negatives increases. Thus, this study needs to be
validated in the U.S. environment, where the rule-in ratecommonly is lower than that reported by our European
colleagues. In fact, in some U.S. studies of patients under-
going a chest pain unit evaluation, the rule-in rate is
reported to be 2% (6–8). This represents a challenging
opulation for any assay. If this new troponin assay is found
o be successful for the identification of discharge candi-
ates in this cohort, it could have even more impact on
urrent hospital processes than projected for the European
opulation.
Another consideration is the specific timing of the
easurement of troponin. The authors indicate that nearly
0% of patients sought treatment within 3 h. This is
mportant because it is reasonable to conclude that in the
inutes immediately after a myocardial infarction, troponin
evels are low. Future research will have to define better the
elationship between symptom onset and troponin elevation
o reassure the clinician that a low troponin, as short as 30
in after symptoms, has the same value as a test run 3 h
ater.
No discussion of ED chest pain is complete without
onsidering the U.S. medicolegal climate, where tort reform
eems to be the odd man out in health care planning. Thus,
he notion that the initial troponin result can be used
otentially to discharge patients may be a hazardous prac-
ice, given the litigation consequences of a missed acute
yocardial infarction. Although not as significant as in
urope, this uniquely American challenge makes it difficult
o implement such a strategy in the United States without
urther validation.
Finally, troponin cutoff points must be considered.
dentifying a very low troponin cutoff point in the chest
ain cohort for whom discharge is reasonable in approx-
mately 15% creates a laboratory assay situation similar to
hat of the natriuretic peptides. Very low levels suggest an
lternative diagnosis, very high levels in the appropriate
resentation are consistent with myocardial infarction,
nd a middle gray zone is where neither exclusion nor
iagnosis of acute myocardial infarction is appropriate,
nd further evaluation is required.
Ultimately, this study by Body et al. (1) represents a
aluable examination of the potential for the newest tro-
onin assays to identify patients at low risk of short-term
dverse outcomes. Significant hurdles still must be over-
ome before it is available and appropriate for use in the
nited States population, but the value of a low high-
ensitivity troponin result has great clinical potential.
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